Pfizer Inc. (PFE) Stake Decreased by Tompkins Financial Corp

Tompkins Financial Corp decreased its holdings in Pfizer Inc. (NYSE:PFE) by 0.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 96,290 shares of the biopharmaceutical company’s stock after selling 843 shares during the period. Pfizer accounts for about 0.9% of Tompkins Financial Corp’s portfolio, making the stock its 26th biggest holding. Tompkins Financial Corp’s holdings in Pfizer were worth $4,202,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Baxter Bros Inc. boosted its stake in shares of Pfizer by 15.2% in the fourth quarter. Baxter Bros Inc. now owns 17,738 shares of the biopharmaceutical company’s stock worth $774,000 after acquiring an additional 2,336 shares during the period. Rossmore Private Capital boosted its stake in Pfizer by 8.4% during the fourth quarter. Rossmore Private Capital now owns 9,065 shares of the biopharmaceutical company’s stock valued at $396,000 after buying an additional 700 shares during the last quarter. Lavaca Capital LLC bought a new position in Pfizer during the fourth quarter valued at approximately $1,222,000. Carlson Capital Management boosted its stake in Pfizer by 4.4% during the fourth quarter. Carlson Capital Management now owns 9,015 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 383 shares during the last quarter. Finally, Landsberg Bennett & Dubbaneh LLC bought a new position in Pfizer during the fourth quarter valued at approximately $2,429,000. 69.49% of the stock is owned by hedge funds and other institutional investors.

In other Pfizer news, EVP Douglas M. Lankler sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $42.75, for a total transaction of $213,750.00. Following the sale, the executive vice president now directly owns 83,592 shares in the company, valued at $3,573,558. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $42.83, for a total value of $642,450.00. Following the sale, the insider now owns 124,994 shares in the company, valued at $5,353,493.02. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 332,526 shares of company stock worth $14,346,539. Company insiders own 0.09% of the company’s stock.

Shares of PFE stock opened at $40.92 on Wednesday. Pfizer Inc. has a 1 year low of $34.37 and a 1 year high of $46.47. The company has a current ratio of 1.57, a quick ratio of 1.33 and a debt-to-equity ratio of 0.52. The company has a market cap of $243.59 billion, a price-to-earnings ratio of 13.64, a P/E/G ratio of 2.54 and a beta of 0.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.01. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. The business had revenue of $13.98 billion for the quarter, compared to the consensus estimate of $13.92 billion. During the same period in the prior year, the business posted $0.62 earnings per share. The company’s quarterly revenue was up 2.0% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer Inc. will post 2.86 earnings per share for the current fiscal year.

A number of brokerages recently commented on PFE. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. Bank of America increased their price target on Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Citigroup reissued a “neutral” rating and set a $41.00 price target on shares of Pfizer in a research note on Wednesday, February 20th. Cantor Fitzgerald reissued a “buy” rating and set a $53.00 price target on shares of Pfizer in a research note on Tuesday, February 19th. Finally, Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Thursday, January 31st. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $45.61.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2019/04/17/pfizer-inc-pfe-stake-decreased-by-tompkins-financial-corp.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Marijuana Stocks Investing Considerations

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.